Skip to main content

Coronavirus: Drugs

Question for Department of Health and Social Care

UIN 70315, tabled on 5 November 2021

To ask the Secretary of State for Health and Social Care, if he will set out his timeframe for making antivirals, molnupiravir and ritonavir, available to clinically extremely vulnerable NHS patients following exposure to covid-19.

Answered on

15 November 2021

On 20 October 2021 we announced that the Government had secured two COVID-19 oral antiviral treatments for United Kingdom patients. Molnupiravir (Lagevrio), one of the antivirals procured, received the Medicines and Healthcare products Regulatory Agency (MHRA) authorisation on 4 November 2021. Deployment of the second antiviral, PF-07321332 (Paxlovid), will depend on MHRA approval, and would be taken with Ritonavir, an antiretroviral already used in combination for other viral disease.

The Government intends to deploy antivirals initially through a national study that will prioritise those who are at most risk to COVID-19, including those National Health Service patients deemed clinically extremely vulnerable. This study will help to identify those who will benefit the most from treatment. We will provide more information on the national study, including information on the timeline, in due course.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.